EHA 2023 | Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML
Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, comments on the frontline treatment of patients with FLT3-ITD-mutated acute myeloid leukemia (AML). Whilst midostaurin with intensive chemotherapy is the current standard of care (SOC) in this setting, several studies are investigating whether newer FLT3 inhibitors can improve the outcomes of this group of patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, Astellas, BerGenBio, Daiichi Sankyo, Genentech, Immunogen–advisory board
Abbvie, Astellas, Daiichi Sankyo, Foghorn–consulting
Abbvie, Astellas, Daiichi Sankyo, FujiFilm, Syndax–research funding (to institution)
